Description

Retatrutide is a novel multi-receptor agonist that targets GLP-1, GIP, and glucagon receptors, showing promise in managing weight and metabolic disorders. Research indicates that Retatrutide can significantly reduce body weight by enhancing satiety, reducing appetite, and increasing energy expenditure. Additionally, Retatrutide has shown potential benefits in improving blood sugar control by enhancing insulin secretion and decreasing glucagon levels, similar to other GLP-1 receptor agonists. Early studies also suggest that Retatrutide may have favorable effects on cardiovascular health and liver fat reduction, offering a comprehensive approach to metabolic health management.

Warning: For Research Purposes Only. Injectables are delivered in a freeze-dried (powder) state, contained within a sterile vial. Use requires: Bacteriostatic Water for reconstitution.